{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Lipella Pharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"LIPO"},"Address":{"label":"Address","value":"United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania."},"CompanyUrl":{"label":"Company Url","value":"https://www.lipella.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Janet Okonski","title":"Director-Clinical Operations"},{"name":"Jonathan Kaufman","title":"Chairman, President, CEO, Secretary & Treasurer"},{"name":"Joseph Janicki","title":"Technology Director"},{"name":"Michael Chancellor","title":"Director & Chief Medical Officer"},{"name":"Michelle Gruber","title":"Operations Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}